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Abstract
Background: Amiodarone is often prescribed in the management of atrial fibrillation (AF) 
but is known to cause significant end-organ toxicities. In this study, we examined the impact 
of amiodarone on all-cause mortality in AF patients with structurally normal hearts.
Methods: We performed a retrospective cohort analysis of all AF patients with structurally 
normal hearts who were prescribed antiarrhythmic drugs (AAD) for rhythm control of AF at 
our institution from 2006 to 2013 (n = 2,077). Baseline differences between the amiodarone 
(AMIO: n = 403) and other AADs (NON-AMIO: n = 1,674) groups were corrected for using 
propensity score matching.
Results: Amiodarone use as first-line therapy decreased significantly with a higher degree of 
prescriber specialization in arrhythmia management (31%, 22%, and 9% for primary care 
physicians, general cardiologists and cardiac electrophysiologists, respectively, p < 0.001). 
After propensity score matching, baseline comorbidities were balanced between the AMIO and 
NON-AMIO groups. Over a median follow-up of 28.2 months (range 6.0–100.9 months), 
amiodarone was associated with increased all-cause (HR 2.41, p = 0.012) and non-cardiac 
(HR 3.55, p = 0.008) mortality, but not cardiac mortality. AF recurrence and cardiac hospi-
talizations were similar between the two study groups.
Conclusions: Amiodarone treatment of AF is associated with increased mortality in patients 
without structural heart disease and therefore should be avoided or only used as a second-line 
therapy, when other AF therapies fail. Adherence to guideline recommendations in the manage-
ment of AF patients impacts clinical outcome. (Cardiol J 2015; 22, 6: 622–629)
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Introduction
Amiodarone is the most commonly used anti-
arrhythmic drug (AAD) for atrial fibrillation (AF) 
in the United States, accounting for 45% of AAD 
prescriptions each year [1]. Accumulating evidence 
has suggested that compared to other AADs, ami-
odarone is associated with increased mortality and 
rates of drug discontinuation due to its significant 
end-organ toxicities [2–5]. This is particularly 
important in AF patients without structural heart 
abnormalities in whom the use of other AADs or 
consideration of catheter ablation are preferred 
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according to the 2006 and the recently published 
2014 American Heart Association/American College 
of Cardiology/Heart Rhythm Society (AHA/ACC/ 
/HRS) AF guidelines, which classify amiodarone as 
a second-line therapy for AF in patients without 
structural heart disease after other AADs [6, 7]. 
Prescribing amiodarone as a first-line agent in this 
patient population is however not uncommon in 
“real world” clinical practice where its impact on 
long-term patient outcomes is unclear. We there-
fore sought to investigate how amiodarone impacts 
the long-term clinical outcomes of AF patients 
without structural heart disease, and whether the 
prescription patterns of amiodarone differ by the 
medical specialty of prescribing physicians.
Methods
Study design
The study is a cohort analysis comparing long-
term outcomes of 2,077 consecutive paroxysmal 
or persistent AF patients without structural heart 
disease, who were prescribed amiodarone vs. other 
AADs at the hospitals and clinics of the University 
of Pittsburgh Medical Center (UPMC) from January 
2006 to November 2013 with the goal of achieving 
rhythm control. The study was approved by the 
University of Pittsburgh Institutional Review Board.
Atrial fibrillation patients without structur-
al heart disease who were prescribed Vaughan 
Williams class IC or class III AAD (flecainide, 
propafenone, sotalol, dronedarone, dofetilide or 
amiodarone) with treatment duration of at least 
6 months were included in the study [8]. The initial 
query of the UPMC electronic medical record and 
pharmacologic database yielded 5,976 AF patients 
who were prescribed with Vaughan Williams class 
IC or class III AAD during the study period, among 
which 3,043 patients were excluded due to pres-
ence of structural heart disease including coronary 
artery disease (n = 2,139), congestive heart failure 
(n = 1,405), severe left ventricular hypertrophy 
(n = 82) or moderate to severe valvular heart 
disease (n = 642). Eleven patients were excluded 
for estimated glomerular filtration rate less than 
30 mL/min at baseline, 81 patients were exclud-
ed for previous use of AADs, and 764 patients 
were excluded for treatment duration of less than 
6 months, yielding a final cohort of 2,077 patients. 
There were no missing data on any of the 2,077 
patients included in the analysis.
The patients were followed from the date of 
first AAD prescription through the date of discon-
tinuation of first AAD with prospective review of 
outpatient and inpatient medical records. Patients 
who died or were lost to follow-up during this 
period were censored at their date of death or last 
encounter. Death was ascertained through review 
of the medical records and the social security death 
index. We assigned patients in our cohort to one of 
two groups: amiodarone (AMIO) group, in which 
amiodarone was prescribed as 1st AAD for rhythm 
control; and non-amiodarone (NON-AMIO) group, 
in which AADs other than amiodarone (dronedar-
one, dofetilide, flecainide, propafenone or sotalol) 
were prescribed as 1st AAD.
Demographic data was obtained from the 
clinical records. Information on comorbidities 
was generated from International Classification 
of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) codes in the clinical database with 
coding algorithms described by Quan et al. [9, 10]. 
The CHA2DS2-VASc score and Charlson comorbid-
ity index were calculated for each patient for risk 
stratification [11, 12]. Information on AAD and 
other cardiac medications was obtained from the 
institutional pharmacologic database and clinical 
notes and orders in the electronic medical record. 
The primary medical specialty of AAD prescribers 
could be ascertained in 1,703 (82.0%) patients (pri-
mary care physician or family doctor [PCP] = 127 
[7.5%], general cardiologist [GC] = 1,047 [61.5%], 
cardiac electrophysiologist [EP] = 529 [31.0%]).
Study endpoints
The primary outcome measures were all-
cause mortality. The secondary outcome measures 
included cardiac mortality, non-cardiac mortality, 
AF recurrence, stroke, admission for any cardiac 
condition, and admission for AF. Causes of death 
were classified into cardiac and non-cardiac, and 
were adjudicated by review of clinical notes, death 
summary, and death certificates. Dates of AF recur-
rence were ascertained from clinical notes docu-
menting recurrence of AF by electrocardiogram, 
electrocardiographic monitors, or recurrence of 
AF symptoms. Causes of hospital admission were 
adjudicated by review of admission notes.
Statistical analysis
Baseline characteristics are presented as 
means ± standard deviation for continuous vari-
ables and as occurrence rates for dichotomous 
variables and were compared using the student’s 
t and c2 tests, respectively. To adjust for differ-
ences in baseline characteristics, propensity score 
matching was performed. Unbalanced baseline 
characteristics (age, sex, CHA2DS2-VASc score, 
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Charlson comorbidity index, hypertension, diabe-
tes, hyperlipidemia, mild valvular heart disease, 
ventricular tachycardia, cerebrovascular disease, 
chronic obstructive pulmonary disease [COPD], 
chronic kidney disease, liver disease, and cancer) 
were included as covariates in the propensity score 
model. Patients were then matched on a 1:1 basis 
between the two study groups using a caliper width 
of 0.10 of the logit of the propensity score. After 
propensity score matching, baseline characteristics 
between patients in each group were calculated 
and compared using the Student’s t and c2 tests. 
Kaplan-Meier curve was constructed for overall 
survival and were compared using the Cox-pro-
portional hazard test. To assess the validity of our 
results, analyses of all end points were repeated 
using all patients by fitting Cox proportional hazard 
models with all baseline characteristics as covari-
ates and then again with propensity scores entered 
as covariates. All tests were 2-tailed, and p-values 
< 0.05 were considered statistically significant. All 
statistical analyses were performed using STATA 
12.1 (StataCorp LP, College Station, Texas).
Results
Study population
The study cohort consisted of 2,077 AF pa-
tients, of whom 403 patients were in the AMIO 
group and 1,674 patients were in the NON-AMIO 
group. The median follow-up time was 28.2 (range 
6.0–100.9) months, 22.4 (range 6.1–100.0) months 
in the AMIO group and 30.1 (range 6.0–100.9) 
months in the NON-AMIO group (p < 0.001). In 
the AMIO group, the mean maintenance dose of the 
medication was 202 ± 49 (range 100–400) mg/day. 
The overwhelming majority (89%) of patients were 
taking 200 mg/day. Table 1 compares the baseline 
characteristics of the study groups. Patients in 
AMIO group were generally older, more likely to 
Table 1. Baseline characteristics.
Amiodarone Non-amiodarone P 
Total 403 1,674
Mean age 74.1 ± 12.0 66.4 ± 12.5 < 0.001
Sex (male) 183 (45.4%) 925 (55.3%) < 0.001
CHA2DS2-VASC score: < 0.001
0–2 138 (34.2%) 1,008 (60.2%)
3–5 231 (57.3%) 597 (35.7%)
6–9 34 (8.4%) 69 (4.1%)
Mean CHA2DS2-VASc score 3.14 ± 1.59 2.24 ± 1.63 < 0.001
Mean Charlson comorbidity index 1.49 ± 1.73 0.95 ± 1.39 < 0.001
Hypertension 281 (69.7%) 970 (58.0%) < 0.001
Valvular heart disease (mild) 97 (24.1%) 203 (12.1%) < 0.001
Ventricular tachycardia 4 (1.0%) 23 (1.4%) 0.544
Atrial flutter 25 (6.2%) 116 (6.95) 0.603
Diabetes mellitus 75 (18.65) 251 (15.05) 0.073
Hyperlipidemia 225 (55.8%) 808 (48.3%) 0.006
Chronic obstructive pulmonary disease 39 (9.7%) 99 (5.9%) 0.006
Chronic kidney disease 47 (9.3%) 54 (3.4%) < 0.001
Cancer 55 (13.7%) 159 (9.5%) 0.014
Medications at baseline:
Anticoagulation 274 (68.0%) 1,167 (69.7%) 0.500
Aspirin 248 (61.5%) 1,061 (63.4%) 0.491
ACEI/ARB 208 (51.6%) 785 (46.9%) 0.089
Beta-blocker 265 (65.3%) 878 (52.5%) < 0.001
Calcium channel blocker 170 (42.2%) 643 (38.4%) 0.164
Statins 192 (47.6%) 769 (45.9%) 0.538 
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blockers
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be female, with higher CHAD2DS2-VASc score, 
higher Charlson comorbidity index, and higher 
rates of hypertension, mild valvular heart disease, 
hyperlipidemia, chronic obstructive lung disease, 
chronic kidney disease and cancer. Rates of anti-
coagulation were similar between the two groups. 
Propensity score matching produced 403 patient 
pairs. After propensity score matching, age and all 
baseline comorbidities were balanced between the 
two groups (Table 2).
Prescribers of antiarrhythmic drugs
Prescribers of AADs were identified in 1,703 
patients, including 313 (77.7%) patients in AMIO 
group and 1,390 (83.0%) patients in NON-AMIO 
group (Table 3). Compared with EP, PCP and 
GC were more likely to prescribe amiodarone as 
a first-line AAD (30.7% PCP vs. 21.7% GC vs. 8.9% 
EP, p < 0.001) for AF patients without structural 
heart disease.
Table 2. Baseline characteristics after propensity score matching.
Amiodarone Non-amiodarone P 
Total 403 403
Mean age 74.1 ± 12.0 74.3 ± 10.9 0.771
Sex (male) 183 (45.4%) 163 (40.5%) 0.155
CHA2DS2-VASC score: 0.617
0–2 138 (34.2%) 129 (32.0)
3–5 231 (57.3%) 233 (57.8)
6–9 34 (8.4%) 41 (10.2)
Mean CHA2DS2-VASc score 3.14 ± 1.59 3.19 ± 1.68 0.698
Mean Charlson comorbidity score 1.49 ± 1.73 1.47 ± 1.78 0.857
Hypertension 281 (69.7%) 276 (68.5%) 0.703
Valvular heart disease (mild) 97 (24.1%) 93 (23.1%) 0.740
Ventricular tachycardia 4 (1.0%) 5 (1.2%) 0.737
Atrial flutter 25 (6.2%) 14 (3.55) 0.071
Diabetes mellitus 75 (18.65) 69 (17.15) 0.581
Hyperlipidemia 225 (55.8%) 232 (57.65) 0.619
Chronic obstructive pulmonary disease 39 (9.75%) 46 (11.45%) 0.422
Cancer 55 (13.7%) 57 (14.1%) 0.839
Medications at baseline:
Anticoagulation 274 (68.0%) 287 (71.2%) 0.319
Aspirin 248 (61.5%) 247 (61.3%) 0.942
ACEI/ARB 208 (51.6%) 194 (48.1%) 0.324
Beta-blocker 265 (65.3%) 183 (45.4%) < 0.001
Calcium channel blocker 170 (42.2%) 148 (36.7%) 0.113
Statins 192 (47.6%) 208 (51.6%) 0.260
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blockers
Table 3. Prescribers of 1st antiarrhythmic drugs.
Amiodarone Non-amiodarone Total
Primary care physician 39 (30.7%) 88 (69.3%) 127
General cardiologist 227 (21.7%) 820 (78.3%) 1,047
Electrophysiologist 47 (8.9%) 482 (91.1%) 529
Total 313 1,390 1,703
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Mortality
In propensity-matched cohort, the AMIO group 
had a higher all-cause mortality rate compared to the 
NON-AMIO group (hazard ratio [HR] 2.41, p = 0.012, 
absolute crude mortality risk increased by 1.68% 
per year; Table 4, Fig. 1). Investigation of cause of 
death revealed that of the 23 deaths in the AMIO 
group, 7 deaths were due to cardiac causes and 
16 to non-cardiac conditions. On the other hand, 
of the 13 deaths in the NON-AMIO group, 7 were 
cardiac deaths and 6 were non-cardiac deaths. The 
non-cardiac deaths in patients on amiodarone in-
cluded respiratory failure (n = 3), cancer (n = 4), 
sepsis (n = 3), pulmonary embolism (n = 1), 
dementia (n = 1), trauma (n = 1), stroke (n = 1), 
and perforated bowels (n = 1). The cause could 
not be determined in 1 patient. Compared to the 
NON-AMIO group, the risk of non-cardiac death 
was significantly higher in the AMIO group (HR 
3.55, p = 0.008, absolute crude non-cardiac mortal-
ity risk increased by 1.49% per year; Table 4). The 
risk of cardiac deaths was similar between the two 
groups (HR 1.40, p = 0.527; Table 4).
Atrial fibrillation recurrence  
and hospitalizations
In the propensity-matched cohort, AF recur-
rence occurred in 111 (27.5%) patients in the AMIO 
group and 140 (34.7%) patients in the NON-AMIO 
group during the follow-up periods. In the AMIO 
group, 69 (17.1%) patients required admission for 
cardiac conditions, including 43 (10.7%) patients 
Figure 1. Overall survival for amiodarone (AMIO) group vs. non-amiodarone (NON-AMIO) group in propensity-
-matched cohort; AAD — antiarrhythmic drugs; HR — hazard ratio.
Table 4. Major clinical outcomes for amiodarone group vs. non-amiodarone group.
   Propensity-matched cohort     Complete cohort
Hazard ratio P Hazard ratio P 
All-cause mortality 2.41 0.012 2.13 0.009
Cardiac mortality 1.40 0.527 1.75 0.293
Non-cardiac mortality 3.55 0.008 2.25 0.021
Atrial fibrillation recurrence 0.93 0.574 0.88 0.227
Stroke 0.73 0.451 0.82 0.622
Cardiac admission 1.13 0.469 1.02 0.870
Atrial fibrillation admission 1.00 0.996 0.89 0.478
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with AF admissions. In the NON-AMIO group, 
75 (18.6%) patients had cardiac admissions, including 
53 (13.2%) with AF admissions. There were no sig-
nificant differences in the risk of AF recurrences, 
stroke, cardiac admissions or AF admissions be-
tween the two groups (Table 4).
Validation of clinical outcomes  
with multivariate model
Multivariate Cox-proportional hazard analy-
sis was performed for the complete cohort (n = 
= 2,077) to validate the results from the propensi-
ty-matched cohort. In the complete cohort, there 
were 23 deaths in the AMIO group (n = 403), 
with 7 cardiac deaths and 16 non-cardiac deaths. 
Thirty-five deaths occurred in the NON-AMIO 
group (n = 1,674), including 10 cardiac deaths 
and 25 non-cardiac deaths. After adjusting for 
baseline characteristics, all-cause mortality was 
significantly higher in the AMIO group (HR 2.13, 
p = 0.009; Table 4), which was primarily driven by 
the higher risk of non-cardiac death in the AMIO 
group (HR 2.25, p = 0.021; Table 4). No significant 
difference was found in cardiac mortality, stroke, 
AF recurrence, cardiac admission, or AF admission 
between the two groups.
Discussion
This cohort study suggests that compared 
with other Vaughan Williams class IC and class 
III AADs, amiodarone therapy in AF patients 
with structurally normal hearts is associated with 
a significant increase in all-cause mortality, driven 
primarily by higher rates of non-cardiac mortality. 
It also suggests that prescribing amiodarone as 
a first-line AAD in this patient population is more 
common among physicians with less specialization 
in arrhythmia management. These results have 
immediate implication for clinical practice.
Amiodarone, a complex iodinated compound, 
has been known for its clinical efficacy as well as 
its potential for serious end-organ toxicities due to 
tissue accumulation with long-term oral therapy, 
mainly in the lungs, liver, thyroid gland, nerves, 
skin, eyes, and heart [2–5, 13, 14]. When the 
Food and Drug Administration granted approval 
for amiodarone in 1985, it was intended for life-
threatening ventricular arrhythmias and could only 
be prescribed by experienced physicians [14]. Over 
time, however, off-label use of amiodarone became 
more common due to its clinical efficacy and safer 
pro-arrhythmic profile compared with other AADs, 
especially among patients with chronic heart failure 
or previous myocardial infarction [3, 5, 15, 16]. 
Analyses of the AFFIRM study suggested that 
among AF patients with pre-existing pulmonary 
disease, the use of amiodarone does not increase 
pulmonary death or all-cause mortality [17] and 
that amiodarone is superior to other AAD in main-
taining sinus rhythm [18]. Presently, amiodarone 
is the most commonly prescribed AAD for AF [5], 
and has gained popularity among physicians of dif-
ferent medical specialties.
Conversely, there has been increasing evi-
dence suggesting that long-term amiodarone use 
may increase mortality and adverse events in AF 
patients. In the SCD-HeFT trial, amiodarone was 
associated with increased non-cardiac mortality in 
patients with New York Heart Association heart 
failure class III [2]. A mixed treatment comparison 
analysis based on data from existing randomized 
control trials showed that, compared to placebo, 
amiodarone was associated with increased all-cause 
mortality (HR 2.73, p = 0.049) and increased odds 
of study withdrawal and drug discontinuation due 
to adverse side effects [3]. In a systematic review 
with direct comparison to dronedarone, amiodarone 
was associated with 9.6 more deaths and 62 more 
adverse events per 1,000 treated patients, resulting 
in discontinuation of the drug, despite lower rates 
of AF recurrence [4].
Our study focused on AF patients without 
structural heart disease, in whom the use of ami-
odarone can usually be avoided since other treat-
ment options with less severe long-term side ef-
fects and toxicities are available and recommended 
according to published guidelines. In our cohort, 
amiodarone was prescribed as a first-line AAD in 
nearly 20% of patients, contrary to recommenda-
tions of the 2006 and 2014 AHA/ACC/HRS AF 
guideline [6, 7]. In a propensity-matched cohort, 
all-cause mortality increased by 2.41 folds in the 
AMIO group, primarily due to a 3.55-fold increase 
in non-cardiac mortality. The cardiac mortality was 
similar between the two groups. The etiology of 
the increase of non-cardiac mortality in the AMIO 
group may be multifold. It is well known that ami-
odarone toxicity, especially pulmonary toxicity, 
could be fatal. However, none of the patients in our 
cohort had pulmonary toxicity documented as the 
cause of death, which is consistent with the pre-
vious literature [16–19]. It is therefore likely that 
amiodarone contributes to worsening overall medi-
cal condition for AF patients, leading to higher rates 
of acute decompensation. For instance, although 
baseline COPD prevalence was similar between 
the two groups in the propensity-matched cohort 
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(9.7% AMIO vs. 11.5% NON-AMIO, p = 0.42), 
5 patients in the AMIO group vs. no patients in 
the NON-AMIO group died of respiratory failure.
In our cohort, amiodarone was more often 
chosen as first-line AAD for AF by providers with 
less specialization in arrhythmia management. 
Considering the fast pace of advancement in elec-
trophysiology, it is conceivable that primary care 
physicians and general cardiologists may be less up 
to date with the latest guidelines in AF management. 
Cardiac electrophysiologists, with more experience 
in rhythm control strategies, may also be more 
comfortable with prescribing other AADs with less 
toxicity. These considerations, which may help ex-
plain the discrepancies in use of amiodarone for AF 
by physician specialty deserve further investigation.
The results of our study suggest that ami-
odarone should be used with more caution in AF 
patients without structural heart disease and only 
after other therapies, including other AAD or 
ablation therapies have been tried and failed. It 
also suggests that strategies of rate control which 
have not been implicated in increased mortality 
rates have also to be considered when possible, 
particularly in asymptomatic or minimally symp-
tomatic patients. Our results also highlight the im-
portance of disseminating to physicians of different 
medical specialties knowledge regarding potential 
amiodarone toxicity and the availability of other 
rhythm control strategies. Whether more effective 
mechanisms for monitoring the potential side ef-
fects of amiodarone may alter patient outcomes is 
unclear at this point, but deserves consideration.
Our retrospective cohort study carries the 
inherent limitations of selection bias and informa-
tion bias. To minimize the impact of selection bias, 
we excluded patients with structural heart disease 
and/or severe chronic kidney disease, so that each 
patient in either group would be eligible to take 
any of the AADs we studied. We then analyzed 
data with propensity-score matching methods 
and multivariate analysis to adjust for differences 
in baseline characteristics. Of note, propensity 
score matching can eliminate biases from observed 
imbalances between groups but cannot adjust for 
unobserved differences. In our cohort, difference 
in use of beta-blockers persisted between the 
groups despites propensity score matching. For 
information bias, the quality of event reporting 
and data collection is overall similar between the 
two study groups, as these data were collected 
simultaneously, using the same institutional elec-
tronic medical record system. For the evaluation 
of clinical outcomes, we focused on the mortality 
risk of long-term amiodarone therapy, which may 
not reflect the full impact of the nonfatal adverse 
effects associated with amiodarone. The external 
validity of the study may be limited by the fact that 
our patient population was from a single center. It 
is worth noting, however, that UPMC comprises 
a network of more than 25 hospitals as well as many 
outpatient clinics encompassing a large geographi-
cal area in Western Pennsylvania. With a cohort of 
2,077 AF patients derived from these sites, this 
study has a wide representation of varying practice 
settings and patient demographics. Lastly, although 
we show in our analysis a 12% reduction in the 
rate of AF recurrence associated with the use of 
amiodarone, this trend did not reach statistical 
significance either because of lack of statistical 
power or because of unaccounted biases between 
the study groups.
Conclusions
Amiodarone use for AF is associated with in-
creased mortality in patients with normal hearts, 
primarily due to increased non-cardiac deaths. It 
should therefore be avoided and only considered 
after other therapies fail. The use of amiodarone as 
a first-line AAD is more common among physicians 
who are less specialized in arrhythmia manage-
ment, suggesting the need for better dissemination 
of the knowledge regarding published guideline 
recommendations on AF management.
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